Efficacy of Alpha Lipoic Acid Supplementation In Chemotherapy-Induced Peripheral Neuropathy
DOI:
https://doi.org/10.32539/bsm.v5i1.162Keywords:
Alpha-lipoic acid, Chemotherapy, Peripheral Neuropathy, Chronic PainAbstract
Background. Chemotherapy-induced peripheral neuropathy is a side effect of several chemotherapy drugs and a significant cause of chronic pain in cancer patients, which affects patients' long-term quality of life. The neurotoxic chemotherapy agents most reported to cause neuropathic pains are platinum and taxane. This study aimed to determine the efficacy of alpha-lipoic acid supplementation in chemotherapy patients.
Methods. This study used a randomized, double-blind clinical trial in the oncology haematology clinic in the Department of Internal Medicine at Mohammad Hoesin General Hospital Palembang from November 2018 to July 2019. Samples were taken from patients who met the inclusion criteria and signed informed consent forms to join the study. This studyused SPSS version 22.0 for Windows to analyze the data.
Results. This research studied 30 subjects who were divided into alpha lipoic acid groups and placebo groups with 15 samples each. The alpha-lipoic acid group showed a significant decline in the Toronto Clinical Scoring System (TCSS) after treatment (p = 0.000) compared to the placebo group (p = 0.164).
Conclusions. Treatment with a 600 mg single dose each day of alpha-lipoic acid for 12 weeks effectively improved patients condition significantly.
Authors
- Mediarty Syahrir1
- Yenny Dian Andayani1
- Norman Djamaludin1
- Erty Sundarita Maksudin1*
- Putri Farissa Muharramah1
- Kgs. M. Rosyidi1
- Hasnawi Haddani2
- Erial Bahar3
- 1Department of Internal Medicine, Faculty of Medicine, Universitas Sriwijaya, Indonesia
- 2Department Neurology, Faculty of Medicine, Universitas Sriwijaya, Indonesia
- 3Department of Anatomy, Faculty of Medicine, Universitas Sriwijaya, Indonesia
Corresponding author Erty Sundarita Maksudin — ertysundarita@gmail.com
Article history
- Submitted
- Accepted
- Published
Downloads
Published
Issue
Section
License
As our aim is to disseminate original research article, hence the publishing right is a necessary one. The publishing right is needed in order to reach the agreement between the author and publisher. As the journal is fully open access, the authors will sign an exclusive license agreement.
The authors have the right to:
- Share their article in the same ways permitted to third parties under the relevant user license.
- Retain copyright, patent, trademark and other intellectual property rights including research data.
- Proper attribution and credit for the published work.
For the open access article, the publisher is granted to the following right.
- The non-exclusive right to publish the article and grant right to others.
- For the published article, the publisher applied for the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
